🇺🇸 Adenosine 5'-triphosphate in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 12

Most-reported reactions

1. Neonatal Disorder — 2 reports (16.67%)
2. Supraventricular Tachycardia — 2 reports (16.67%)
3. Acidosis — 1 report (8.33%)
4. Blood Alkaline Phosphatase Increased — 1 report (8.33%)
5. Cognitive Disorder — 1 report (8.33%)
6. Covid-19 — 1 report (8.33%)
7. Decreased Appetite — 1 report (8.33%)
8. Eye Pain — 1 report (8.33%)
9. Eyelid Disorder — 1 report (8.33%)
10. Heart Rate Decreased — 1 report (8.33%)

Source database →

Frequently asked questions

Is Adenosine 5'-triphosphate approved in United States?

Adenosine 5'-triphosphate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Adenosine 5'-triphosphate in United States?

McMaster University is the originator. The local marketing authorisation holder may differ — check the official source linked above.